Strahlentherapie des Mediastinalen Hodgkin-Lymphoms

Literaturverzeichnis
Gilbert, R., and Babaiantz, L. (1931). Notre methode de roentgentherapie de la lymphogranulomatose
(Hodgkin): resultats eloignes. Acta Radiol 12, 523-529.
Ginzton, E.L., Mallory, K.B., and Kaplan, H.S. (1957). The Stanford medical linear accelerator. I. Design and
development. Stanford Med Bull 15, 123-140.
Girinsky, T., Pichenot, C., Beaudre, A., Ghalibafian, M., and Lefkopoulos, D. (2006a). Is intensity-modulated
radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for
mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and
dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64, 218-226.
Girinsky, T., Specht, L., Ghalibafian, M., Edeline, V., Bonniaud, G., Van Der Maazen, R., Aleman, B., Paumier,
A., Meijnders, P., Lievens, Y., Noordijk, E., and Poortmans, P. (2008). The conundrum of Hodgkin lymphoma
nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group
guidelines. Radiother Oncol 88, 202-210.
Girinsky, T., van der Maazen, R., Specht, L., Aleman, B., Poortmans, P., Lievens, Y., Meijnders, P.,
Ghalibafian, M., Meerwaldt, J., and Noordijk, E. (2006b). Involved-node radiotherapy (INRT) in patients with
early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79, 270-277.
Glick, J.H., Young, M.L., Harrington, D., Schilsky, R.L., Beck, T., Neiman, R., Fisher, R.I., Peterson, B.A., and
Oken, M.M. (1998). MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves
failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 16, 19-26.
Goodman, K.A., Toner, S., Hunt, M., Wu, E.J., and Yahalom, J. (2005). Intensity-modulated radiotherapy for
lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62, 198-206.
Goodman, L.S., Wintrobe, M.M., and et al. (1946). Nitrogen mustard therapy; use of methyl-bis (betachloroethyl)
amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease,
lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 132, 126-132.
Haedinger, U., Krieger, T., Flentje, M., and Wulf, J. (2005). Influence of calculation model on dose distribution
in stereotactic radiotherapy for pulmonary targets. Int J Radiat Oncol Biol Phys 61, 239-249.
Hagemeister, F.B., Tannir, N., McLaughlin, P., Salvador, P., Riggs, S., Velasquez, W.S., and Cabanillas, F.
(1987). MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent
Hodgkin's disease. J Clin Oncol 5, 556-561.
Halbsguth, T., and Borchmann, P. (2010). Therapiestrategien für die Behandlung des Hodgkin-Lymphoms bei
älteren Patienten. Der Onkologe 16, 55-62.
Hall, E.J. (2006). Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat
Oncol Biol Phys 65, 1-7.
Hall, E.J., and Wuu, C.S. (2003). Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J
Radiat Oncol Biol Phys 56, 83-88.
Hancock, S.L., Cox, R.S., and McDougall, I.R. (1991). Thyroid diseases after treatment of Hodgkin's disease. N
Engl J Med 325, 599-605.
Hancock, S.L., Tucker, M.A., and Hoppe, R.T. (1993). Factors affecting late mortality from heart disease after
treatment of Hodgkin's disease. JAMA 270, 1949-1955.
Hasenclever, D., and Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease. International
Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339, 1506-1514.
Heidenreich, P.A., Hancock, S.L., Lee, B.K., Mariscal, C.S., and Schnittger, I. (2003). Asymptomatic cardiac
disease following mediastinal irradiation. J Am Coll Cardiol 42, 743-749.
Heidenreich, P.A., and Kapoor, J.R. (2009). Radiation induced heart disease: systemic disorders in heart disease.
Heart 95, 252-258.
Heuser, E., Behringer, K., Engert, A., and Diehl, V. (2007). Hodgkin-Lymphom. In Therapiekonzepte
Onkologie, S. Seeber, ed. (Heidelberg: Springer), pp. 318-341.
Heutte, N., Flechtner, H.H., Mounier, N., Mellink, W.A., Meerwaldt, J.H., Eghbali, H., van't Veer, M.B.,
Noordijk, E.M., Kluin-Nelemans, J.C., Lampka, E., Thomas, J., Lugtenburg, P.J., Viterbo, L., Carde, P.,
Hagenbeek, A., van der Maazen, R.W., Smit, W.G., Brice, P., van Marwijk Kooy, M., Baars, J.W., Poortmans,
P., Tirelli, U., Leeksma, O.C., Tomsic, R., Feugier, P., Salles, G., Gabarre, J., Kersten, M.J., Van Den Neste, E.,
Creemers, G.J., Gaillard, I., Meijnders, P., Tertian, G., Reman, O., Muller, H.P., Troncy, J., Blanc, M.,
Schroyens, W., Voogt, P.J., Wijermans, P., Rieux, C., Ferme, C., and Henry-Amar, M. (2009). Quality of life
127